Aldeyra Therapeutics, Inc. ALDX
Nov 3, 2026, 3:42 PM EST
- YTD
- -88.08%
- 1 year
- -88.20%
- Market cap
- 37.23M
- EPS (ttm)
- -0.38
- Shares out
- 59.55M
- Forward P/E
- -7.80
- YTD return
- -88.08%
- 1-year return
- -88.20%
- Volume
- 605.52K
- Avg volume
- 1.16M
- Open
- 0.5832
- Previous close
- 0.5832
- Day's range
- 0.5526 – 0.63
- 52-week range
- 0.527 – 5.93
- Beta
- 1.43
- Analysts
- Strong Buy
- Price target
- 10.00 (+1520.2%)
- Earnings date
- Oct 3, 2024
5m -0.0228 (-3.56%)
Key statistics
- Enterprise value
- 233.47M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -57.67M
- Total cash
- 72.74M
- Total debt
- 15.61M
- Return on equity
- -43.05%
- Short % of float
- 6.90%
- 50-day average
- 5.12
- 200-day average
- 4.48
Analyst view
Consensus: strong buy
- Target (low)
- 8.00
- Target (mean)
- 10.00
- Target (high)
- 12.00
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 3, 2024
Expected Oct 3, 2024. Consensus EPS estimate -0.21731.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.25 | -0.25 | 0.00 | 0.00% |
| Oct 3, 2024 | Jun 1, 2024 | -0.21 | — | — | — |
| May 2, 2024 | Mar 1, 2024 | -0.08 | -0.14 | -0.06 | -75.00% |
| Mar 7, 2024 | Dec 1, 2023 | -0.21 | -0.08 | +0.13 | +61.90% |
| Nov 3, 2023 | Sep 1, 2023 | 0.00 | -0.14 | — | — |
| Aug 3, 2023 | Jun 1, 2023 | -0.31 | -0.15 | +0.16 | +51.61% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 6, 2024 | Oppenheimer | reit | Outperform | Outperform |
| May 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 3, 2024 | Oppenheimer | up | Perform | Outperform |
| Oct 17, 2023 | Citigroup | main | Buy | Buy |
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aldeyra.com
News
12 Health Care Stocks Moving In Friday's After-Market Session 
12 Health Care Stocks Moving In Tuesday's After-Market Session - 12 Health Care Stocks Moving In Monday's Intraday Session
HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target 
Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally 
Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally 
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease Transcript 
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target 
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease 
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
Your note
Sign in to keep a note on ALDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRADY TODD C | Chief Executive Officer | Sale | Mar 11, 2024 | 1,471,300 |
| BRONSTEIN BEN | Director | Conversion of Exercise of derivative security | Jun 26, 2023 | 28,248 |
| GREENBERG BRUCE | Chief Financial Officer | Sale | Aug 11, 2024 | 126,382 |
| MACHATHA STEPHEN | Officer | Sale | Aug 11, 2024 | 236,771 |
| MILLER-RICH NANCY | Director | Purchase | Apr 11, 2023 | 922 |
| PERCEPTIVE ADVISORS L L C | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 4, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 15.58% | 9,275,851 | 44.11M | Sep 29, 2024 |
| Knoll Capital Management, LLC | 9.19% | 5,475,516 | 26.04M | Sep 29, 2024 |
| Vanguard Group Inc | 6.32% | 3,760,619 | 17.88M | Sep 29, 2024 |
| Blackrock Inc. | 6.27% | 3,734,408 | 17.76M | Sep 29, 2024 |
| Kennedy Capital Management, Inc. | 3.16% | 1,881,078 | 8.94M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.87% | 1,114,628 | 5.30M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.95% | 1,758,714 | 8.36M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.18% | 1,296,318 | 6.16M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.17% | 697,567 | 3.32M | Sep 29, 2024 |
| Vanguard Explorer Fund, Inc. | 1.14% | 680,004 | 3.23M | Jul 30, 2024 |
| Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF | 1.07% | 635,905 | 3.02M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.86% | 510,128 | 2.43M | Aug 30, 2024 |